Office-use compounding in Indiana

What the rule requires in practice

Each item carries a confidence level. Verbatim rule text is high confidence; a reading of how two provisions interact, or a source that could not be re-verified, is not.

The scope limit, and it must be carriedHigh confidence

The whole of IC 16-42-22.5 is titled "Drugs: Restrictions on Bulk Drug Substances", and the first four conditions of § 3(a) all presuppose a bulk substance — its grade, the registration status with the federal regulator of the establishment that made it, a valid certificate of analysis, and quality control testing. Conditions (5) and (6), the federal-compliance limbs the verdict rests on, sit in that same list. For compounding from active pharmaceutical ingredient — which is what peptide compounding is — the section bites squarely. For compounding from finished dosage forms it is a live textual argument, and a page must not claim otherwise.A flat "Indiana prohibits office-use compounding" is therefore overbroad and would be wrong for compounding from finished dosage forms. The construction that survives is that Indiana bars non-compliant compounding from bulk drug substances and independently gates sterile compounding to a prescription.

The federal precondition runs the opposite way to a conduitHigh confidence

Several states in this file authorise office use "in accordance with federal law", which authorises nothing because it hands the question back. Indiana does the inverse: it forbids compounding unless federal law is satisfied, and IC 16-42-22.5-4(a) requires a pharmacy subject to the federal compounding section to comply with it and its regulations. The federal patient-specific condition therefore becomes an independent Indiana requirement rather than a federal one Indiana declined to address.

The second, independent gate — and what it reveals about the rulebookHigh confidence

Article 1 of 856 IAC runs to 44 rules and contains no general compounding rule. Rule 30, on sterile products, is the only compounding-adjacent one, and its purpose clause gates it to preparation "pursuant to a drug order or prescription". Non-sterile compounding has no board rule at all. There is no office-use permission to find because Indiana never built the shelf to put one on.

Veterinary compounding is outside the chapter entirelyHigh confidence

IC 16-42-22.5-0.5 provides that the chapter does not apply to the compounding of, or to a compounded, drug for animal use. Indiana does not create a broader animal channel so much as decline to regulate it in this chapter.

No office-use label legendHigh confidence

The only practitioner-delivery label Indiana prescribes is patient-specific: IC 16-42-19-11(a)(2) requires the container to bear directions, the practitioner’s name and address, and the name of the patient, and the sterile rule says the same for products dispensed to a patient. Indiana’s only "not for resale" language sits inside the possession exemption as a condition on it, not as a labelling requirement — quoting it as a legend is a misreading.

The enforcement edge is criminalHigh confidence

IC 25-26-13-29(a)(2) makes it unlawful for any person to accept a prescription for filling or compounding at a place or facility that does not hold a valid pharmacy permit, and the offence is a Level 6 felony. The moment compounding happens on a clinic’s premises without a pharmacy permit, that provision is in play — which is a different and sharper risk than the licensing questions on the rest of this page.

Indiana has two 5%-style clauses, one of them uncappedHigh confidence

IC 25-26-14-11(9) excludes from wholesale distribution the sale of a drug by a retail pharmacy to a practitioner for office use where the gross dollar value stays under five percent of the pharmacy’s total legend drug sales over twelve consecutive months; (12) separately excludes the sale of minimal quantities to licensed practitioners for office use, with no percentage at all. Both are exemptions from the definition of wholesale distribution, and their only effect is that the selling pharmacy escapes distributor licensure.These two are the only place the phrase "office use" appears in Indiana’s pharmacy statutes, which is exactly why they get misread as a permission. They do not touch the compounding chapter, the legend-drug possession provisions, or the sterile rule. Two sharpening details: the "5% cap" framing is itself incomplete for Indiana because (12) has no cap, and both limbs run to a practitioner defined as an individual — so a sale invoiced to a management company is outside the carve-out on its face.

Entity or person — Indiana is the outlier, and it cuts the permissive wayHigh confidence

Elsewhere in this file the finding "no entity credential exists" is restrictive. In Indiana it is permissive. IC 16-42-19-21 exempts from the legend-drug prohibitions not only pharmacists and practitioners, who are named individuals, but persons who procure legend drugs for handling by or under the supervision of pharmacists or practitioners employed by them, and institutions that procure legend drugs for lawful administration by practitioners. Those are genuine entity limbs. A company employing practitioners may lawfully procure and possess legend drugs for handling under their supervision — there is no credential to obtain, and none is needed.Controlled substances work differently. IC 35-48-3-3(c) does create a real entity credential in the form of an owner registration, but IC 35-48-3-1.5(b) exempts entities in which more than fifty percent of the owners are themselves listed practitioners. A physician-majority-owned practice needs no owner registration; a med spa owned mostly by non-practitioners does.

A new entity credential is arriving, and not from the pharmacy boardHigh confidence

IC 25-22.5-12.5 took effect 1 July 2026 and makes medical-spa registration mandatory from 1 January 2027, issued by the Medical Licensing Board of Indiana, with the procedure to be established by 1 October 2026. The application must state whether the medical spa engages in or plans to engage in compounding as the new chapter defines it, and operating unregistered draws a fine of up to $5,000. A physician’s office, and a facility or practice otherwise licensed by the state, are excluded from the definition.

Last change, and what is still movingHigh confidence

IC 16-42-22.5 was created by 2026 legislation and came into force on 1 July 2026, so the governing chapter is new and secondary sources predating it describe a different Indiana. A first semiannual compounding oversight report falls due 1 September 2026 and must count 503A pharmacies and medical spas by licence type. The Board of Pharmacy’s compounding rule subcommittee has been rewriting 856 IAC 1-30 across several meetings and a new rule is contemplated, with nothing published in the Indiana Register yet.

Indiana at a glance

Receiving 503B office stock in Indiana

Indiana is the rare state where the board has said out loud that the category does not exist, and it is on the record in its own minutes. The route is a wholesale distributor licence by default, with an exemption the licensing agency gestures at and never prints.

Everything above this heading answers the supply question: may a state-licensed 503A pharmacy ship non-patient-specific stock? This section answers the other half. Registration with FDA under section 503B is a federal exemption from federal law and preempts no state licensing scheme, so it is never the whole answer on its own — a state credential is the norm rather than the exception, it is not always issued by the board of pharmacy, and in some states the category you would search for does not exist. What Indiana asks for is set out below, including where we could not establish it.

What the 503B must hold to ship inMedium confidence

A wholesale drug distributor licence from the Board of Pharmacy under the Professional Licensing Agency. There is no outsourcing-facility category: the board’s own minutes of 10 March 2025 record an applicant being told "Indiana does not license 503Bs", and the application was withdrawn. IC 25-26-14-14(a) requires NABP accreditation as well as the licence and fee, IC 25-26-14-1(a) reaches entities located inside or outside Indiana, and no provisional licence is available to an out-of-state applicant.Medium, and the reason is a live ambiguity nobody in Indiana has resolved on the record. IC 25-26-14-1(b) provides that, except as required by federal law, the chapter does not apply to "a manufacturer that is approved by the federal Food and Drug Administration" — and a facility registered with FDA as an outsourcing facility under section 503B is registered, not approved in the sense that phrase normally carries. The agency’s own licensing page compounds it by saying licensure applies unless an exemption applies and then never printing the exemption list it promises. The term "outsourcing facility" appears nowhere in the relevant titles or board articles, and the agency’s facility-licence catalogue contains no such type and no drug-manufacturer type at all.

Does your practice need a permit?High confidence

No permit exists to hold stock, and none is needed: the possession exemption at IC 16-42-19-21 covers practitioners and, unusually, entities that procure legend drugs for handling by practitioners they employ. The exposure is on the other side of the line — compounding on the premises without a pharmacy permit is a Level 6 felony under IC 25-26-13-29(a)(2).From 1 January 2027 a medical spa must register with the Medical Licensing Board, and the application asks whether it compounds. That is a registration for the business model rather than a drug credential, and it is issued by a different board again.

Administer vs dispenseMedium confidence

The possession exemption reaches procurement and handling, and the institutional limb names procurement "for lawful administration by practitioners" expressly, so administration is the clean case. Dispensing pulls in the patient-specific labelling requirements at IC 16-42-19-11(a)(2), which assume a named patient, and compounding on site pulls in the pharmacy-permit offence.

Scheduled (controlled) stockHigh confidence

Yes, and twice over. IC 35-48-3-3(g) requires a separate registration at each principal place of business or professional practice where the applicant handles controlled substances and employs or contracts with individuals to dispense them, and the board rule requires a separate registration for each principal place of business at one general physical location. There is also an owner registration for the entity, subject to the practitioner-majority-ownership exemption noted above.Materiality caveat worth keeping in view: compounded peptides and the GLP-1 class are legend drugs rather than scheduled substances, so the controlled-substance registration is largely beside the point for this vertical. It bites only if a shipment actually contains controlled substances.

How to check a facility’s credential before you order is set out in how to place an office-use order.

What this page does not establish

• The governing chapter could not be re-fetched live, and it still cannot be linked. The legislature’s site is a JavaScript application that returns a 691-byte application shell for every path — the reader route, the PDF-document endpoint and the publications tree alike — and its data interface requires a key; the administrative-code host answers with a comparable stub. The two chapters created in 2026 are also too new for the mirrors, which carry the 2025 code. So this page deliberately publishes no link for IC 16-42-22.5, IC 25-22.5-12.5 or 856 IAC 1-30: there is no host these can be retrieved from, and a citation that resolves to a shell would look sourced while citing nothing. The text here was verified against the legislature’s own bulk download of the code rather than against a live fetch, and it is internally consistent in its section numbering, its "as added by" stamps and its table of contents. It is nonetheless the one state on this page whose verification is not independent of the corpus it came from.
• Whether the Board treats a 503B outsourcing facility as exempt under the FDA-approved manufacturer limb of IC 25-26-14-1(b) is unresolved, and is handled case by case at board meetings. It decides the receiving side, and the agency page that promises an exemption list never prints one.
• Whether the bulk-drug-substance chapter reaches compounding from finished dosage forms is a live textual question. The verdict on this page is stated with that limit attached rather than without it.
• Indiana has no rule for non-sterile compounding at all, and its board is actively rewriting the sterile one with nothing yet published. Both facts limit how long this page can be relied on.
• We searched no case law, attorney-general opinions or disciplinary orders for this state, and search engines were unavailable when it was researched. Read nothing into that silence — it means we have not looked, not that nothing is there.